Directed evolution of stabilized monomeric CD19 for monovalent CAR interaction studies and monitoring of CAR-T cell patients
E Laurent, A Sieber, B Salzer, A Wachernig… - ACS Synthetic …, 2021 - ACS Publications
CD19 is among the most relevant targets in cancer immunotherapy. However, its
extracellular domain (ECD) is prone to aggregation and misfolding, representing a major …
extracellular domain (ECD) is prone to aggregation and misfolding, representing a major …
Retargeting CD19 chimeric antigen receptor T cells via engineered CD19-fusion proteins
JR Klesmith, L Su, L Wu, IA Schrack… - Molecular …, 2019 - ACS Publications
CD19-targeted chimeric antigen receptor (CAR) T-cells (CAR19s) show remarkable efficacy
in the treatment of relapsed/refractory acute lymphocytic leukemia and Non-Hodgkin's …
in the treatment of relapsed/refractory acute lymphocytic leukemia and Non-Hodgkin's …
Getting CD19 into shape: expression of natively folded “difficult-to-express” CD19 for staining and stimulation of CAR-T cells
E Lobner, A Wachernig, V Gudipati… - … in Bioengineering and …, 2020 - frontiersin.org
The transmembrane protein CD19 is exclusively expressed on normal and malignant B cells
and therefore constitutes the target of approved CAR-T cell-based cancer immunotherapies …
and therefore constitutes the target of approved CAR-T cell-based cancer immunotherapies …
Recombinant human CD19 in CHO-K1 cells: glycosylation patterns as a quality attribute of high yield processes
M Billerhart, M Hunjadi, V Hawlin… - International Journal of …, 2023 - mdpi.com
CD19 is an essential protein in personalized CD19-targeting chimeric antigen receptor
(CAR)-T cell-based cancer immunotherapies and CAR-T cell functionality evaluation …
(CAR)-T cell-based cancer immunotherapies and CAR-T cell functionality evaluation …
[HTML][HTML] Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy
S Fiorenza, SYT Lim, GS Laszlo, EL Kimble… - Molecular Therapy …, 2024 - cell.com
Current CD33-targeted immunotherapies typically recognize the membrane-distal V-set
domain of CD33. Here, we show that decreasing the distance between T cell and leukemia …
domain of CD33. Here, we show that decreasing the distance between T cell and leukemia …
The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28
YD Muller, DP Nguyen, LMR Ferreira, P Ho… - Frontiers in …, 2021 - frontiersin.org
Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on-and off-rates against …
Background Commercial anti-CD19 chimeric antigen receptor T-cell therapies (CART19)
are efficacious against advanced B-cell non-Hodgkin lymphoma (NHL); however, most …
are efficacious against advanced B-cell non-Hodgkin lymphoma (NHL); however, most …
Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response
Q Xue, E Bettini, P Paczkowski, C Ng, A Kaiser… - … for immunotherapy of …, 2017 - Springer
Background It remains challenging to characterize the functional attributes of chimeric
antigen receptor (CAR)-engineered T cell product targeting CD19 related to potency and …
antigen receptor (CAR)-engineered T cell product targeting CD19 related to potency and …
Targeting CD22 for B-cell hematologic malignancies
J Xu, W Luo, C Li, H Mei - Experimental Hematology & Oncology, 2023 - Springer
CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
Robust antitumor activity and low cytokine production by novel humanized anti-CD19 CAR T cells
Recent studies have described the remarkable clinical outcome of anti-CD19 chimeric
antigen receptor (CAR) T cells in treating B-cell malignancies. However, over 50% of …
antigen receptor (CAR) T cells in treating B-cell malignancies. However, over 50% of …